Macular oedema following rituximab infusion in two patients with Wegener's granulomatosis

Clinical and Experimental Rheumatology

Volumn 28, Issue 1 SUPPL. 57, 2010, Pages

  Bussone, Guillaume ^a   Kaswin, Godefroy ^a   De Menthon, Mathilde ^a   Delair, Emmanuelle ^a   Brézin, Antoine P ^a   Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cystoid macular oedema; Rituximab; Scleritis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB; TRIAMCINOLONE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CASE REPORT; CORTICOSTEROID THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LUNG BIOPSY; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINA MACULA EDEMA; SCLERITIS; VISUAL ACUITY; WEGENER GRANULOMATOSIS; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; ASTHENIA; BEST CORRECTED VISUAL ACUITY; COMPUTER ASSISTED TOMOGRAPHY; CYTOPENIA; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; LUNG INFILTRATE; LUNG NODULE; MACULAR EDEMA; PARANASAL SINUSITIS; RELAPSE; RHINITIS; SEROUS OTITIS MEDIA; SINUSITIS;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MACULAR EDEMA; MIDDLE AGED; TOMOGRAPHY, OPTICAL COHERENCE; WEGENER GRANULOMATOSIS;

EID: 77954568844     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. PAKROU N, SELVA D, LEIBOVITCH I: Wegener's granulomatosis: ophthalmic manifestations and management. Semin Arthritis Rheum 2006; 35: 284-92.
2. BUSSONE G, HACHULLA E, SIBILIA J et al.: [Treatment of systemic autoimmune and inflammatory diseases with rituximab]. Presse Med 2009; 38: 808-23.
3. SEO P, SPECKS U, KEOGH KA: Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35: 2017-23.
4. SANCHEZ-CANO D, CALLEJAS-RUBIO JL, ORTEGO-CENTENO N: Effect of rituximab on refractory Wegener granulomatosis with predominant granulomatous disease. J Clin Rheumatol 2008; 14: 92-3.
5. ROCCATELLO D, BALDOVINO S, ALPA M et al.: Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008; 26 (Suppl. 49): S67-71.
6. BRIHAYE B, AOUBA A, PAGNOUX C, COHEN P, LACASSIN F, GUILLEVIN L: Adjunction of rituximab to steroids and immuno-suppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25 (Suppl. 44): S23-7.
7. TAYLOR SR. SALAMA AD, JOSHI L, PUSEY CD, LIGHTMAN SL: Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60: 1540-7.
8. ONAL S, KAZOKOGLU H, KOC A, YAVUZ S: Rituximab for remission induction in a patient with relapsing necrotizing scleritis associated with limited Wegener's granulomatosis. Ocul Immunol Inflamm 2008; 16: 230-2.
9. MARTINEZ DEL PERO M, CHAUDHRY A, JONES RB, SIVASOTHY P, JANI P, JAYNE D: B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study. Clin Otolaryngol 2009; 34: 328-35.
10. ARIES PM, HELLMICH B, VOSWINKEL J et al.: Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-8.
11. JABS DA, MUDUN A, DUNN JP, MARSH MJ: Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol 2000; 130: 469-76.
12. MONNET D, MOACHON L. DOUGADOS M, BREZIN AP: Severe uveitis in an HLA-B27-positive patient with ankylosing spondylitis. Nat Clin Pract Rheumatol 2006; 2: 393-7.
13. TAPPEINER C, HEINZ C, SPECKER C, HEILIGENHAUS A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007; 39: 184-6.